Sophie Lucas - Targeting GARP on Tregs: a novel approach for cancer immunotherapy ?
Key | Action |
---|---|
K or space | Play / Pause |
M | Mute / Unmute |
C | Select next subtitles |
A | Select next audio track |
V | Show slide in full page or toggle automatic source change |
left arrow | Seek 5s backward |
right arrow | Seek 5s forward |
shift + left arrow or J | Seek 10s backward |
shift + right arrow or L | Seek 10s forward |
control + left arrow | Seek 60s backward |
control + right arrow | Seek 60s forward |
shift + down arrow | Decrease volume |
shift + up arrow | Increase volume |
shift + comma | Decrease playback rate |
shift + dot or shift + semicolon | Increase playback rate |
end | Seek to end |
beginning | Seek to beginning |
Informations sur ce média
Nombre de vues :
18 (ce mois : 1)Date de création :
mai 14, 2018Lien vers la chaîne du média :
Autres videosDescription
Regulatory T lymphocytes (Tregs) are essential to prevent auto-immunity, but excessive Treg function contributes to cancer progression by inhibiting anti-tumor immune responses. Tregs exert contact-dependent inhibition of immune cells through the production of active TGF-β1. On the Treg cell surface, TGF-β1 is in an inactive form bound to membrane protein GARP and then activated by an unknown mechanism. We demonstrate that GARP is involved in this activation mechanism. We generated anti-human GARP monoclonal antibodies that block the production of active TGF-β1 by human Tregs. These antibodies recognize a conformational epitope that requires amino-acids GARP137-139 within GARP/TGF-β1 complexes. A variety of antibodies recognizing other GARP epitopes did not block active TGF-β1 production by human Tregs. In a model of xenogeneic graft-versus-host disease in NSG mice, blocking antibodies inhibited the immunosuppressive activity of human Tregs. We also derived anti-murine GARP antibodies that block active TGF-β1 production by mouse Tregs. These antibodies inhibit the growth of P815 mastocytoma in DBA/2 mice when used as monotherapies. Altogether, our data show that anti-GARP antibodies may serve as therapeutic tools to boost immune responses to infection or cancer, via a mechanism of action distinct from that of currently available immunomodulatory antibodies. Used alone or in combination with other therapeutic reagents, blocking anti-GARP antibodies may improve the efficiency of cancer immunotherapy.
Prof. Sophie Lucas - Duve Institute, Université catholique de Louvain (UCL), Brussels, Belgium
I acquired an M.D. degree in 1994 and a Ph.D. degree in 2000 for my work in the field of tumour immunology under the mentorship of Prof. Thierry Boon. I identified and characterised novel genes encoding human tumour-specific antigens, some of which were used in clinical trials of therapeutic vaccination against cancer. My early post-doctoral work was devoted to studying new cytokines and cytokine receptors in the laboratory of F. de Sauvage at Genentech, a bio-technological company located in San Francisco (USA). In 2004, I founded my own research group at the de Duve Institute (Faculty of Medicine, UCL, Brussels). The long-term objective of my research is to identify molecular mechanisms by which regulatory T cells (Tregs) inhibit anti-tumour T cell responses, with the hope to develop targeted strategies to improve the efficacy of cancer immunotherapy. My work is now focused on identifying the molecular mechanisms by which regulatory T cells inhibit anti-tumour immune responses in cancer patients, with a particular emphasis on the production of active TGF-β, a cytokine with potent immune suppressive functions.
Autres médias dans la chaîne "Autres videos"
- 53 vues, 2 ce moisConsultation et laboratoire de génétique20 juillet 2023
- 5 vues, 1 ce moisProjet Estuaire (laboratoires IREENA, LTeN)24 janvier 2023
- 29 vues, 1 ce moisInstitut des substances et organismes de la mer - ISOMER12 juillet 2022
- 262 vues, 1 ce mois3 questions à... Catherine de Charette, directrice de la Fondation Nantes Université27 juin 2022
- 1346 vues, 1 ce moisÉlections Nantes Université - 3 questions à Carine Bernault17 décembre 2021
- 71 vues, 1 ce moisLe point sur les élections avec Marc Renner, administrateur provisoire de Nantes Université4 novembre 2021